ACM
AZN icon

Anfield Capital Management’s AstraZeneca AZN Stock Holding History

Anfield Capital Management’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.9K Buy
+385
New +$74.2K 0.02% 210
2025
Q3 		– Sell
-8
Closed -$1.05K – 610
2025
Q2 		$1.05K Buy
+8
New +$1.12K ﹤0.01% 475

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Asset Management
Vanguard Asset Management London, Ec4n 8af $148B AUM

Anfield Capital Management's AZN Position: Q1 2026 in Review

Anfield Capital Management opened a new position in AstraZeneca (AZN) in Q1 2026: 385 shares worth $75.9K. The stake represents 0.02% of the portfolio and ranks #210 among its holdings. This is a return to the name: Anfield Capital Management previously reported a position in AZN as recently as Q2 2025.

Anfield Capital Management first reported a position in AZN in Q2 2025 and has held it in 2 quarters since. 1,383 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Anfield Capital Management held 385 shares of AstraZeneca worth $75.9K as of Q1 2026.
  • AstraZeneca was a new Anfield Capital Management position in Q1 2026.
  • AstraZeneca made up 0.02% of Anfield Capital Management's portfolio in Q1 2026, its #210 holding.
  • Anfield Capital Management first reported a position in AstraZeneca in Q2 2025 and has held it in 2 quarters since.
  • 1,383 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Anfield Capital Management's 13F filing for Q1 2026, filed 12 May 2026.